Sentences with phrase «ovarian tumor cells»

The researchers have devised a nanosensor that breaks apart in the presence of ovarian tumor cells and sheds fragments of itself.

The resulting «map» of gene - drug interactions allowed the researchers to accurately predict the responses of multiple human cancer cell lines to different chemotherapy agents based on the cell lines» genetic profiles and also revealed new genetic factors that appear to determine the response of breast and ovarian tumor cells to common classes of chemotherapy treatment.

«We found a striking difference between the metabolic profiles of poorly aggressive and highly aggressive ovarian tumor cells, particularly with respect to their production and use of the amino acid glutamine,» said lead researcher Deepak Nagrath of Rice.

Claudin - 4 activity in ovarian tumor cell apoptosis resistance and migration.

Not exact matches

Chemotherapy drugs designed to kill tumors may actually encourage ovarian cancer by stimulating the growth of cells that give rise to the malignancy, a new study finds.

Shih, Wang and their colleagues tested fostamatinib's power to reduce tumor size in mice implanted with human ovarian cancer cells that were resistant to paclitaxel.

The research shows that ONA reduces the progression of malignant ovarian cancer tumors by interfering with the pro-tumor function of myeloid cells.

«In pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies.»

The study published in Cancer Cell shows that exosomes from tumor cells of breast cancer (and other tumor types such as ovarian and endometrial) are different in size and composition than those of healthy cells.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

One study showed that ovarian tumors produce a signaling molecule that serves to attract regulatory T cells, a subclass of adaptive immune cells responsible for quieting other T cells.

The lab of co-author Dr. Robert Bast Jr., an expert in ovarian cancer and vice president for translational research at MD Anderson, inserted gel - bound carbon nanotubes into the ovaries of rodents to mimic the accumulations that are expected for nanotubes linked to special antibodies that recognize tumor cells.

Researchers at Rice University's Laboratory for Systems Biology of Human Diseases analyzed the metabolic profiles of hundreds of ovarian tumors and discovered a new test to determine whether ovarian cancer cells have the potential to metastasize.

Their results demonstrate that specific rhoptry and dense granule effector proteins that T. gondii secretes before and after host cell invasion, respectively, control the development of an effective host antitumor response, and increase the survival of mice with ovarian tumors.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

«We think that by isolating the CA125 - negative tumor cells we have uncovered this reservoir of carboplatin - resistant high - grade serous ovarian cancer cells.»

«We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment,» says Minko.

While previous research had shown some effectiveness of this molecule in a mouse model of ovarian cancer, that benefit was limited by the immunosuppressive environment within tumors, particularly the presence of regulatory T cells (Tregs).

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells — which kill infected and cancerous cells — and demonstrates how they can be identified and selectively grown for use in personalized, cell - based immunotherapies.

The 3 ovarian cancer cases diagnosed before age 18 years were germ cell tumors and included in the analysis (Table 1).

And a December 2014 study found that ovarian tumors coax adult stem cells into providing key metabolites they need to grow.

Next they treated the experimental tumor cells with MIR506 to determine if it would behave in the same way it had with ovarian and other cancers.

The earliest and one of the most striking came from observations that the presence of infiltrating T cells (called «tumor - infiltrating lymphocytes,» or TILs) in ovarian tumors is positively and strongly associated with improved survival of patients with ovarian cancer [1].

This separation may not be restricted to ovarian cancer, or to the NCI60 panel of tumor cells, they suggest, but could apply to a multitude of tumor types.

He previously revealed the existence of spontaneous immune responses in ovarian tumors as well as described how regulatory T cells and tumor blood vessels affect these responses.

The authors studied a standard panel of 60 established human tumor cell lines representing nine different human cancers, as well as several specimens of human primary ovarian cancer.

Their theory was first confirmed with ovarian cancer cell lines and then the Peter / Lengyel team tested HGMA2 protein levels in tumor samples from 100 patients with ovarian cancer.

The companies have launched a phase II trial of the antibody - drug conjugate, and are also testing it in other solid tumors, including ovarian and non — small - cell lung cancers.

[2] Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8 + tumor - infiltrating lymphocytes and a high CD8 + / regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

$ 1.8 M Supports Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung Cancer Ribbon?

NK cells are a key part of the innate immune system with the ability to recognize and kill diverse types of tumor cells, including ovarian cancer.

The tumor - suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK / Rho signaling pathways.

Growth inhibition of ovarian tumor - initiating cells by niclosamide.

Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient.

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

STC2 overexpression could promote tumor cell proliferation, invasion, and metastasis in prostate cancer, ovarian cancer, or neuroblastoma.

Dr. Matsuzaki has accumulated extensive expertise in T - cell biology and mechanisms of immune suppression in periphery and tumor microenvironments in patients with ovarian cancer.

Matsuzaki J, Gnjatic S, Mhawech - Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. (2010) NY - ESO - 1 specific tumor infiltrating CD8 + T cells in human ovarian cancer: negative regulation by LAG - 3 and PD - 1.

The approach developed by the MGH team starts with the engineered protein, which in this case fuses an antibody fragment targeting a protein called mesothelin — expressed on the surface of such tumors as mesothelioma, ovarian cancer and pancreatic cancer — to a protein from the tuberculosis bacteria that stimulates the activity of dendritic and other immune cells.

«Visualizing how cancer cells interact with a tumor microenvironment that accurately reflects the complex biology of ovarian cancer should help us understand the mechanisms underlying metastatic progression as well as identify new therapeutics that can inhibit this process,» said clinical gynecologic oncologist Ernst Lengyel, MD, PhD, senior author of the study and a professor of obstetrics and gynecology at the University of Chicago.

A novel approach to cancer immunotherapy — strategies designed to induce the immune system to attack cancer cells — may provide a new and cost - effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.

In the experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells» processing and presentation of several different tumor antigens, inducing a number of T - cell - based immune responses.

Tags: checkpoint inhibitors, Clinical Research, immunotherapy, Lung Cancer, McGarry Houghton, Ovarian Cancer, pembrolizumab, Philip D Greenberg, solid tumors, T cell, t cell therapy, Transplant and Immunotherapy

Curcumin has been clinically shown to inhibit growth of various cancer cells including: Bone Cancer, Breast Cancer, Brain Tumors, Colon, Liver, Pancreatic, Stomach, Bladder, Kidney, Prostate, Leukemia, Ovarian, Melanoma, and more!

The prolonged heat may also be the result of persistent high level of estrogen provoked by an ovarian cyst or by a granulosa cell tumor of the ovary.

Granulosa cell and epithelial tumors are the most common ovarian tumors in bitches.

Tumors of ovarian stromal cells include granulosa cell tumors, thecomas and interstitial cell tumors (luteTumors of ovarian stromal cells include granulosa cell tumors, thecomas and interstitial cell tumors (lutetumors, thecomas and interstitial cell tumors (lutetumors (luteomas).

Some gerbils can have spontaneous seizures, ovarian cysts, tumors, and squamous cell carcinomas.